Cancer Nanotechnology

$18,550P30FY2014CANIH

University Of California Los Angeles, Los Angeles CA

Investigators

Linked publications & trials

Paper 39710854 Paper 39677814 Paper 39677813 Paper 39589879 Paper 39554138 Paper 39554127 Paper 39484366 Paper 39386450 Paper 39325056 Paper 39294048 Paper 39282325 Paper 39272889 Paper 39228741 Paper 39169899 Paper 39158404 Paper 38982561 Paper 38968117 Paper 38839950 Paper 38771648 Paper 38723698 Paper 38719809 Paper 38713004 Paper 38626853 Paper 38585946 Paper 38518770 Paper 38511933 Paper 38464266 Paper 38412093 Paper 38370678 Paper 38354231 Paper 38341660 Paper 38341658 Paper 38325563 Paper 38270802 Paper 38181796 Paper 38082117 Paper 38059331 Paper 38048400 Paper 38045310 Paper 37919520 Paper 37902809 Paper 37871333 Paper 37812335 Paper 37809067 Paper 37803324 Paper 37801341 Paper 37762169 Paper 37754663 Paper 37730274 Paper 37655659 Paper 37559183 Paper 37520728 Paper 37482512 Paper 37435085 Paper 37398351 Paper 37366057 Paper 37357983 Paper 37353093 Paper 37333286 Paper 37333052 Paper 37322036 Paper 37294422 Paper 37292767 Paper 37289038 Paper 37280220 Paper 37260544 Paper 37214856 Paper 37196065 Paper 37192158 Paper 37179121 Paper 37160922 Paper 37156551 Paper 37152809 Paper 37140454 Paper 37128507 Paper 37126232 Paper 37094160 Paper 37086408 Paper 37083641 Paper 37069149 Paper 37066394 Paper 37064017 Paper 37053013 Paper 37037616 Paper 37000164 Paper 36980702 Paper 36971339 Paper 36948187 Paper 36930646 Paper 36929731 Paper 36923158 Paper 36922590 Paper 36906850 Paper 36890230 Paper 36884217 Paper 36880064 Paper 36876496 Paper 36860908 Paper 36856617 Paper 36795805

Abstract

PROJECT SUMMARY (See instructions): The Cancer Nanotechnology (CN) Program Area was formed in 2011 upon the strong advice of our EAB. CN Program Area aims are to: 1) engineer, test and deliver therapeutic anti-cancer nanoparticles; 2) develop nanoscale imaging and mechanics to detect, quantify and track cancers; 3) invent and refine surface, analytic and manipulative nanoscale platforms; and 4) integrate systems biology and translate promising approaches into preclinical and early phase clinical testing. The Program Area is led by Michael Teitell, MD, PhD (UCLA) and James Heath, PhD (Caltech). UCLA and Caltech have several longstanding, beneficial collaborations, including a combined Medical Scientist Training Program (MSTP), a Joint Center for ? Translational Medicine (JCTM) and an NCI-funded Center of Cancer Nanotechnology Excellence (CCNE). The CN Program Area combines the strengths of these two leading institutions to facilitate the translation of discoveries in nanotechnology into advances against cancer. As with other Program Areas, the JCCC fosters numerous interactions and many of the JCCC's Shared Resources support investigators in the CN Program Area. The CN Program Area is comprised of 26 members, including four

View original record on NIH RePORTER →